This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benotti, J. R. Articles by Carabello, B. A. Search for Related Content PubMed PubMed Citation Articles by Benotti, J. R. Articles by Carabello, B. A.

Circulation, Vol 62, 28-34, Copyright © 1980 by American Heart Association

ARTICLES

Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease

JR Benotti, W Grossman, E Braunwald and BA Carabello

Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown. Accordingly, the hemodynamic, myocardial metabolic and ECG responses to amrinone (2.5 mg/kg i.v. over 1 hour) were measured in nine patients with congestive heart failure secondary to coronary artery disease. Increases were observed in cardiac index (1.3 +/- 0.4 to 2.2 +/- 0.7 l/min/m2) and left ventricular stroke work (10.6 +/- 3.0 to 19.2 +/- 6.3 g-m/m2), and decreases in mean pulmonary wedge (31 +/- 5 to 26 +/- 4 mm Hg), mean pulmonary artery (44 +/- 8 to 36 +/- 7 mm Hg) and mean right atrial pressures (18 +/- 4 to 10 +/- 4 mm Hg), myocardial arteriovenous oxygen difference (129 +/- 19 to 109 +/- 17 ml/l), CBF (215 +/- 117 to 178 +/- 84 ml/min) and MVO2 (27 +/- 14 to 19 +/- 9 ml/min). All changes were significant (p less than 0.01). No significant changes occurred in aortic mean pressure, heart rate, myocardial lactate extraction or ECG, and no patient developed angina. In explaining the decline in MVO2, it is possible that the increase in contractility was more than offset by the reductions in preload and afterload. The amrinone-induced hemodynamic improvement in patients with congestive heart failure secondary to coronary artery disease was associated with reductions in MVO2 and CBF and no evidence of myocardial ischemia.

This article has been cited by other articles:

				S. M. Hollenberg, C. J. Kavinsky, and J. E. Parrillo Cardiogenic Shock Ann Intern Med, July 6, 1999; 131(1): 47 - 59. [Abstract] [Full Text] [PDF]

				J. C. Sill, B. Bertha, I. Berger, C. Uhl, M. Nugent, and J. Folts Human Platelet Ca2+ Mobilization, Glycoprotein IIb/IIIa Activation, and Experimental Coronary Thrombosis In Vivo in Dogs Are All Inhibited by the Inotropic Agent Amrinone Circulation, September 2, 1997; 96(5): 1647 - 1653. [Abstract] [Full Text]

				R. Gitter, J. M. Anderson Jr, and G. K. Jett Influence of Milrinone and Norepinephrine on Blood Flow in Canine Internal Mammary Artery Grafts Ann. Thorac. Surg., May 1, 1996; 61(5): 1367 - 1371. [Abstract] [Full Text]

				J. A. FRANCIOSA Intravenous Amrinone: An Advance or a Wrong Step? Ann Intern Med, March 1, 1985; 102(3): 399 - 400. [Abstract] [PDF]

				R. E. RUDE, J. E. MULLER, and B. EUGENE Efforts to Limit the Size of Myocardial Infarcts Ann Intern Med, December 1, 1981; 95(6): 736 - 761. [Abstract] [PDF]